Histone deacetylase inhibition modulates cell fate decisions during myeloid differentiation

BACKGROUND: The clinical use of chromatin-modulating drugs, such as histone deacetylase inhibitors, for the treatment of bone marrow failure and hematopoietic malignancies has increased dramatically over the last few years. Nonetheless, little is currently known concerning their effects on myelopoie...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Bartels, Marije, Geest, Christian R., Bierings, Marc, Buitenhuis, Miranda, Coffer, Paul J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Ferrata Storti Foundation 2010
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2895027/
https://ncbi.nlm.nih.gov/pubmed/20107159
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2009.008870
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak